Abstract
Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. Participants: We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventy-eight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7±9.3 years were included in this analysis. Intervention: Patients were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab and underwent Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Repeated-measures analysis of variance was used to compare mean values. Main Outcome Measures: Changes in BCVA, OCT, and FA. Results: Mean follow-up was 6.31±0.81 months (range, 6-9). Sixteen (20.5%) eyes needed a second injection at a mean of 13.8 weeks (range, 4-28), and 6 eyes needed a third injection (7.7%) at a mean of 11.5 weeks (range, 5-20). The mean baseline BCVA was 0.87 (logarithm of the minimum angle of resolution), and the final mean BCVA was 0.6, a difference that was statistically significant (P
| Original language | English (US) |
|---|---|
| Pages (from-to) | 743-750 |
| Number of pages | 8 |
| Journal | Ophthalmology |
| Volume | 114 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2007 |
Fingerprint
ASJC Scopus subject areas
- Ophthalmology
Cite this
Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema. Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up. / Arevalo, J Fernando; Fromow-Guerra, Jans; Quiroz-Mercado, Hugo; Sanchez, Juan G.; Wu, Lihteh; Maia, Mauricio; Berrocal, Maria H.; Solis-Vivanco, Adriana; Farah, Michel E.
In: Ophthalmology, Vol. 114, No. 4, 04.2007, p. 743-750.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema. Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up
AU - Arevalo, J Fernando
AU - Fromow-Guerra, Jans
AU - Quiroz-Mercado, Hugo
AU - Sanchez, Juan G.
AU - Wu, Lihteh
AU - Maia, Mauricio
AU - Berrocal, Maria H.
AU - Solis-Vivanco, Adriana
AU - Farah, Michel E.
PY - 2007/4
Y1 - 2007/4
N2 - Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. Participants: We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventy-eight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7±9.3 years were included in this analysis. Intervention: Patients were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab and underwent Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Repeated-measures analysis of variance was used to compare mean values. Main Outcome Measures: Changes in BCVA, OCT, and FA. Results: Mean follow-up was 6.31±0.81 months (range, 6-9). Sixteen (20.5%) eyes needed a second injection at a mean of 13.8 weeks (range, 4-28), and 6 eyes needed a third injection (7.7%) at a mean of 11.5 weeks (range, 5-20). The mean baseline BCVA was 0.87 (logarithm of the minimum angle of resolution), and the final mean BCVA was 0.6, a difference that was statistically significant (P
AB - Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. Participants: We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventy-eight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7±9.3 years were included in this analysis. Intervention: Patients were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab and underwent Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Repeated-measures analysis of variance was used to compare mean values. Main Outcome Measures: Changes in BCVA, OCT, and FA. Results: Mean follow-up was 6.31±0.81 months (range, 6-9). Sixteen (20.5%) eyes needed a second injection at a mean of 13.8 weeks (range, 4-28), and 6 eyes needed a third injection (7.7%) at a mean of 11.5 weeks (range, 5-20). The mean baseline BCVA was 0.87 (logarithm of the minimum angle of resolution), and the final mean BCVA was 0.6, a difference that was statistically significant (P
UR - http://www.scopus.com/inward/record.url?scp=33947581702&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947581702&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2006.12.028
DO - 10.1016/j.ophtha.2006.12.028
M3 - Article
VL - 114
SP - 743
EP - 750
JO - Ophthalmology
JF - Ophthalmology
SN - 0161-6420
IS - 4
ER -